Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Technologies Prices $200M Public Offering

NEW YORK – NanoString Technologies announced late on Wednesday that it plans to offer 5 million shares of common stock at $40 per share in a public offering.

The expected gross proceeds of $200 million are $50 million more than the firm said earlier this week it expected to raise. NanoString has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the offering price; if the underwriters exercise their option in full, the gross proceeds would be approximately $230  million.

The Seattle-based genomics technology firm said it intends to use the proceeds for working capital and general corporate purposes. The offering is expected to close on or about Oct. 13, 2020.

JP Morgan, UBS, and Cowen are acting as joint book-running managers. Baird is acting as manager for the offering.

Earlier this week, NanoString reported preliminary third quarter 2020 revenues of $30.1 million, up 14 percent year over year.

NanoString has raised capital through a public offering each of the last several years, beginning in 2017. Net proceeds from last year's offering were approximately $68.3 million.

In morning trading on the Nasdaq, shares of NanoString were down 4 percent at $40.26.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.